The case for phages begins with their biology. Phages are the most abundant biological entities on Earth, with an estimated population exceeding 10 to the 31st particles, roughly ten times the number of bacteria. In the gut, they dominate the virome and continuously shape bacterial populations through predation and horizontal gene transfer. For therapeutic purposes, the critical distinction lies between lytic and temperate phages. Lytic phages attach via receptor-binding proteins on their tails to specific bacterial surface receptors, inject their nucleic acid, hijack the host’s biosynthetic machinery, and then use phage-encoded holins and endolysins to rupture the cell wall, releasing tens to hundreds of progeny virions. This self-amplifying yet self-limiting cycle, in which phage populations decline once susceptible hosts fall below a threshold, makes strictly lytic phages the preferred candidates for therapy.

Temperate phages, by contrast, integrate into the host chromosome or persist as plasmids and are generally excluded from therapeutic preparations for three reasons: they cannot guarantee immediate bactericidal activity, they can carry virulence genes that increase pathogen fitness, and they facilitate the spread of antibiotic resistance genes through specialized transduction. The review stresses that any phage intended for intestinal health management should be verified by genomic sequencing to confirm the absence of integrase genes, virulence factors, and resistance markers. Host specificity, determined by the molecular match between tail proteins and bacterial receptors such as lipopolysaccharides, outer membrane proteins, pili, flagella, and capsular polysaccharides, is the phage’s fundamental advantage over broad-spectrum antibiotics, which indiscriminately strip out beneficial organisms like Lactobacillus and Bifidobacterium species and undermine colonization resistance.

The protective mechanisms extend well beyond direct killing. By reducing pathogen loads, phages interrupt the inflammatory cascades that damage the intestinal barrier. Tight junction complexes built from occludin, claudin family proteins, and zonula occludens-1 regulate paracellular permeability, and pathogens such as C. perfringens with its NetB toxin, Salmonella with its type III secretion system effectors, and pathogenic E. coli with EspF all converge on disrupting these junctions. In Salmonella Enteritidis-infected chicken intestinal epithelial cells, phage treatment reduced adhesion and invasion, upregulated tight junction gene expression, and suppressed pro-inflammatory mediators including NF-κB p65, TNF-α, and IL-6. In piglets challenged with enterotoxigenic E. coli K88, phage therapy increased jejunal villus height, lowered serum markers of permeability such as diamine oxidase and d-lactate, and raised ZO-1 protein expression.

Microbiota modulation follows a similar logic of ecological cascade. When phages eliminate pathogens, vacated niches can be recolonized by beneficial bacteria, including butyrate-producing taxa whose short-chain fatty acids further reinforce barrier integrity. The Salmonella-targeting cocktail SalmoFree reduced pathogen abundance in broilers while enriching beneficial taxa without disrupting the core cecal community. In weaned piglets, an ETEC-specific phage corrected microecological disturbances and increased Shannon diversity. In dairy cows, metagenomic and metabolomic analyses revealed coordinated succession of the rumen phageome and bacteriome across lactation, with phage-mediated lysis reshaping volatile fatty acid production, particularly propionate, and ultimately milk protein synthesis efficiency. Yet the review is careful to note that most of this evidence comes from 16S rRNA amplicon surveys of relative abundance, in which depleting one taxon mathematically inflates the apparent abundance of others, so niche liberation remains an inference until confirmed with absolute quantification in adequately powered studies.

Immune regulation adds a further dimension. By cutting pathogen-associated molecular pattern release, phages dampen excessive TLR/NF-κB signaling. A comparative study found that phage therapy attenuated aberrant increases in IL-1β, IL-6, IFN-γ, IL-8, and IL-12 while raising anti-inflammatory IL-10 and IL-4, without adversely affecting lymphocyte subsets, in contrast to enrofloxacin under the tested conditions. Emerging evidence also suggests direct interactions: phage particles can be internalized by epithelial cells and antigen-presenting cells, and in Salmonella-infected chickens a phage cocktail appeared to attenuate antiviral signaling at the level of IRF3 phosphorylation, limiting excessive inflammation. However, immune recognition cuts both ways, since neutralizing antibodies or accelerated clearance could undermine treatment, and ex vivo work with bovine blood cells showed that immune responses to phages are highly phage-dependent.

The experimental record includes striking successes but also instructive failures. Oral phage administration in a necrotic enteritis model reduced intestinal lesion scores to levels comparable with uninfected controls. Phage STP-1 reduced Salmonella Typhimurium colonization in piglets and improved daily gain, and prophylactic phage P-GXEC-L2P5 prevented edema disease in a Shiga toxin-producing E. coli model. But a feedlot trial in steers found that groups shedding high fecal phage titers after doses up to 4.8 times 10 to the 11th plaque-forming units showed no reduction in E. coli O157:H7 shedding, and spray application of phage failed to protect broilers against respiratory colibacillosis whereas intratracheal delivery was completely protective. A Campylobacter phage cocktail effective under controlled conditions reduced cecal loads in only one of three commercial flocks, a signature of ecological mismatch between phages selected against limited strain panels and the genetically diverse field populations that turn over during production cycles.

Application strategy emerges as decisive. Efficacy is dose-dependent but non-linear, and low-dose or low-activity phages may even induce resistance. Timing matters: prophylactic administration of a phage against Salmonella Pullorum in SPF broilers outperformed delayed therapeutic dosing, yet in another broiler model Salmonella levels rebounded eight days after phage withdrawal. Formulation technology addresses the gastrointestinal gauntlet of acid, bile, and enzymes, which differs sharply by species. In poultry, free phages were inactivated under conditions mimicking the proventriculus and gizzard, whereas Eudragit-encapsulated phages survived and delivered efficiently across a 42-day production cycle. In swine, calcium carbonate-supplemented alginate-carrageenan microcapsules limited phage loss to less than half a log after an hour at pH 2, compared with complete inactivation of free phage within ten minutes below pH 3. Ruminants pose the hardest problem, requiring rumen bypass on top of acid resistance, and phage-specific encapsulation evidence there is largely absent.

Resistance is inevitable but manageable. Bacteria defend themselves by mutating or modifying surface receptors or by deploying restriction-modification, CRISPR-Cas, and abortive infection systems. Encouragingly, resistance often carries fitness costs, such as reduced epithelial colonization in phage-resistant E. coli with LPS defects or increased antibiotic susceptibility in resistant Salmonella. Cocktail strategies targeting multiple receptors, such as O-antigen, BtuB, and OmpC in Salmonella, significantly lower the frequency of phage-insensitive mutants, and rationally designed combinations can steer resistant mutants toward more severe fitness costs. Phage-antibiotic synergy and phage-derived endolysins offer complementary routes, though both require further validation in livestock systems.

Commercial translation is the final hurdle. Downstream processing, particularly endotoxin removal from lysates produced in Gram-negative hosts, is a principal bottleneck, although purification stringency should be matched to the administration route, since oral and feed applications deliver phages into an already LPS-rich intestinal environment. A bioprocess model for a six-phage Salmonella cocktail in Colombian broilers estimated that a single 156-liter bioreactor with filtration could supply roughly 35 percent of the national broiler market at a production cost of about two US cents per chicken, with phage titer rather than downstream recovery as the dominant cost driver. Combined phage-probiotic strategies show promise, including a pre-post farm intervention associated with a 90 percent reduction in Salmonella detection and 72 percent lower mortality, but the review cautions that probiotics can themselves serve as phage hosts and that compatibility must be tested strain by strain. The overall verdict is measured: phages are a credible tool for intestinal health management in an era of antibiotic reduction, but predictable field performance will demand pre-trial surveillance of target strains, monitoring of anti-phage immunity, site-level exposure reporting, and replicated commercial validation before the laboratory promise becomes routine practice.

Subject of Research: Bacteriophage mechanisms and applications for regulating intestinal health in livestock and poultry

Article Title: Mechanisms and Application of Bacteriophages in Regulating Intestinal Health of Livestock and Poultry

Article References: Song, M., Fan, Y., Zhang, L., Qi, W., Li, L., Zhao, G., & He, J. (2026). Mechanisms and Application of Bacteriophages in Regulating Intestinal Health of Livestock and Poultry. MicrobiologyOpen, 15(5), Article e70443. https://doi.org/10.1002/mbo3.70443

Image Credits: AI Generated

DOI: 10.1002/mbo3.70443

Keywords: bacteriophages, livestock, poultry, intestinal health, antimicrobial resistance, Salmonella, microbiota, phage therapy, microencapsulation, animal nutrition, food safety, gut barrier